The Director of the National Investment Agency under the President of the Kyrgyz Republic Talantbek Imanov met with the General Director of 'Rosatom Kyrgyzstan' Dmitry Konstantinov, as well as representatives of other specialized companies, individual ministries and agencies of the Kyrgyz Republic and Russia

During the meeting, they discussed a project for the development of the existing nuclear medicine department (radiopharmaceutical pharmacy and PET-CT department) based at the National Center for Oncology and Hematology of the Ministry of Health of the Kyrgyz Republic into a centralized radiopharmaceutical pharmacy, a molecular imaging center, a radionuclide targeted therapy and theranostics center. As is known, cardiovascular pathology, malignant neoplasms, neurological and other socially significant diseases occupy leading positions in the structure of mortality in the republic. The main problems in managing patients with these nosological forms are late diagnosis, lack of opportunities for clarifying studies, and high-tech personalized targeted treatment. Modern effective tools for solving these problems are nuclear medicine technologies (NM), namely the use of radiopharmaceutical drugs (RPD) for diagnostic or therapeutic purposes.